Artificial Intelligence in the Life Sciences

Precision medicine aims to advance our ability from a "one-size-fits-all" approach to personalized and predictive healthcare across diverse populations. It promotes integration of multi-omics and phenotypic data to understand disease mechanisms and discover novel biomarkers and risk factors, which could be used to predict and prevent critical diseases in individual patients across diverse populations. The potential implications of precision medicine approach can accelerate our ability to classify patients at higher risk of developing critical diseases, improve diagnostic capabilities, develop deeper understanding of individual risk, investigate racial differences and demographic characteristics, and find relationships between genetic variants, expressions, and diseases. This study focuses on implementing an innovative and data driven framework of translational bioinformatics and Machine Learning (ML) techniques to analyze multi-omics, including RNA-seq and Whole-Genome Sequencing (WGS) data, generated using blood samples of randomly consented patients. First, we utilized bioinformatics pipelines to identify differentially expressed genes and their pathogenic and likely pathogenic variants for the downstream data analysis, annotation, and visualization. Then, applied a nexus of ML models for multi-omics biomarker discovery, disease prediction, density-based clustering, single-patient profiling, and pathogenicity classification. WGS data analysis supported the exploration of genetic variation and diversity among patients to identify known and novel biomarkers, whereas RNA-seq data analysis improved our understanding of functional and biological pathways that underlying disease states. We classified and clustered pathogenic variants and expressions across various genes and discovered numerous diseases leading risk factors. Our results include gene-disease associations and captured common pathways across the broader population, demonstrating a level of sensitivity and accuracy that has broad clinical implications. We validated our results through clinical records, and state of the science literature. This study delves into the strengths of multi-omics data integration and capabilities of ML application in genetically diverse and complex patient cohorts. Our approach has the potential to elucidate complex gene-disease interactions for genetically diverse populations, which can support earlier diagnoses for patients in many disease realms.

Objective: To systematically evaluate pathway-informed polygenic risk score (PRS) strategies and determine which approaches most effectively leverage biological annotations for risk prediction, using brain amyloid-beta positivity as a case study. Methods: We systematically benchmarked approaches for integrating pathway information into PRS construction to predict brain A{beta} positivity. Using two cohorts, the Alzheimer's Disease Neuroimaging Initiative (ADNI, n = 969) and Australian Imaging, Biomarkers and Lifestyle (AIBL, n = 251), we compared Apolipoprotein E (APOE) genetic risk score (GRS), clumping and thresholding (C+T) PRS, pathway-guided single nucleotide polymorphism (SNP) selection PRS, and pathway-specific PRSs ensembled via machine learning. Pathways were derived from manually curated literature or from pathway databases via Functional Mapping and Annotation (FUMA). Results: In cross-validation on the ADNI cohort, pathway-informed PRS using a narrow-set of pathways to guide SNP selection (PathPRS-SNPLit without APOE locus) significantly outperformed the standard PRS model (median AUC = 0.742, p = 0.006) and the APOE locus model (median AUC = 0.736, p = 5.1 x 10-5) based on the Mann-Whitney U test, achieving a median AUC of 0.763. This model showed enhanced ability to identify subgroups within the 10% lowest- and highest-risk groups compared to the current standard of APOE locus alone (odds ratio = 0.67, 95% CI: 0.56-0.81; and OR = 13.23, 95% CI: 10.23-17.11), highlighting its clinical potential. Using a focused set of literature-curated pathways outperformed using a broader set of database-derived pathways across configurations. When contrasting strategies for aggregating information across pathways, we observed that using pathways to guide selection of SNPs and then building a single PRS performed comparably to building PRS for each pathway and using machine learning (ML) to aggregate these, though the latter enabled pathway-level interpretability. Similar trends were observed in the external AIBL validation dataset. Interpretation: Pathway-informed PRS can meaningfully improve genetic risk enrichment for A{beta} positivity beyond APOE and standard C+T approaches, provided pathway definitions are carefully curated. The choice of pathway source has the strongest impact on predictive performance, with aggregation strategies or ML model choice having far less impact. Our findings highlight the utility of literature-curated, pathway-informed PRSs for A{beta} prediction and offer practical guidance for pathway-informed PRS construction in other polygenic traits.

Machine learning (ML) is being considered to help diagnose cardiovascular diseases (CVD). Still, challenges like inconsistent and limited datasets, limited infrastructure, and global inequalities lead to the need for a reliable and practicable ML solution. This paper presents an ML-driven framework for predicting CVD risk scores and classifying status. Several data preprocessing techniques, including multiple imputation by chained equations (MICE), outlier removal, are considered. In addition, hyperparameter tuning is performed with the GridSearchCV tuning technique. Moreover, a consensus-driven five-feature selection method is applied to identify optimal predictors. The dataset used in this study contains healthcare records related to future CVD risk scores, comprising 1,529 patient records with 22 features. The optimized stacked ensemble model is applied to the dataset and achieves a cross-validated coefficient of determination value of 98.13% for CVD risk score regression. Comparative evaluation with other ML models confirmed improved accuracy, efficiency, and interpretability. The explainable AI technique SHAP is applied to interpret predictions and highlight key risk factors. Moreover, a deployment-ready web platform with multi-role access has been developed that demonstrates clinical applicability. The proposed framework offers a reliable and interpretable tool for early detection of CVD and personalized risk assessment. In the future, this work can be extended to integrate longitudinal data, medical imaging, and deep learning to improve generalizability and strengthen real-world impact.

Background: Adverse drug events (ADEs) are a critical indicator of patient safety but are often documented only in free-text clinical notes. The potential of recent advances in natural language processing (NLP), particularly generative large language models (LLMs), to identify ADEs remains understudied. This study aimed to compare the performance of multiple LLMs in identifying ADE-Drug relationships in inpatient and ambulatory clinical notes. Methods: We used clinical notes from the 2018 National NLP Clinical Challenge (n2c2) ADE dataset (inpatient; n=505) and from outpatient encounters (n=2,555) between October 1, 2018, and December 31, 2019, at a large academic medical center based in New England. Notes were pre-processed into snippets for model input. Evaluated Models included: GPT-4o, GPT-4o-mini, LLAMA 3.3-70B and their instruction fine-tuned variants (including low-rank adapters for LLAMA). Performance was assessed using both strict and relaxed evaluations (precision, recall, and F1) for all models, followed by manual evaluation (exact semantic match, partial match, missing ADE, drug mention only, not a drug, or wrong) of the two best-performing models. Results: GPT-4o and GPT-4o-mini were the top-performing models among those evaluated. GPT-4o consistently outperformed GPT-4o-mini in ADE extraction across both datasets, with higher F1-scores (0.524 vs. 0.381) and a more balanced precision-recall profile. Both models captured ADEs effectively in explicit and complex clinical contexts, although limitations included misclassification of pre-existing allergies and occasional conflation of therapeutic indications with adverse effects. GPT-4o achieved higher exact match coverage and fewer errors across clinical notes, indicating more reliable performance in both inpatient and ambulatory settings. Conclusion: This work establishes a foundation for integrating LLM methods into real-world drug safety surveillance, with direct implications for improving patient safety.

Background: The impact of the Inflation Reduction Act (IRA) upon late-stage developments has been assumed to be limited. The Congressional Budget Office's IRA analysis excluded post-approval innovation, potentially overlooking substantial economic risks to drug developers and declines in the availability of treatments in areas of high unmet medical need such as oncology. Methods: A total of 1148 secondary trials from 364 FDA-approved medicines, published from 2018 to 2025, were obtained from Biomedtracker and clinicaltrials.gov. Using fractional multinomial logit, we model the share distribution of secondary indication studies across 19 disease groups and assess the change in this distribution post-IRA. We also assessed the number of secondary treatment studies pre- vs. post-IRA using multiple linear regression. Results: After the IRA's introduction, small molecule follow-on studies in oncology exhibited a statistically significant 35% decline (R2 = .48, p < 0.014) and lead indication small molecule oncology approvals exhibited a statistically significant 27% decline (R2 = .70, p < 0.002). We also find a statistically significant 14% decline in the share of orphan oncology studies pre- vs. post-IRA (p<0.001). Research Conclusions: This study's results refute claims that the IRA would have minimal negative effects on patient access or late-stage biopharmaceutical R&D. We hope this study reinvigorates debate about the law's unintended consequences and encourages thoughtful policy solutions, as the IRA manifestly creates disincentives that negatively impact patients seeking needed new medicines, particularly those requiring cures addressing metastatic late-stage cancers.

Artificial intelligence (AI) tools have been rapidly adopted by medical researchers, yet whether early career researchers in low and middle income countries possess the awareness and habits needed to use these tools safely remains poorly documented. This study characterized AI adoption patterns, hallucination awareness, and verification and disclosure practices among early career medical researchers in Pakistan. A cross sectional anonymous online survey was conducted among medical students, house officers, residents, physicians, and faculty involved in research or academic work across Pakistan (May 2026). Descriptive statistics and chi square tests were applied to 373 eligible responses. AI use was near universal (99.7%), with 60.3% using AI tools daily. The most commonly reported tool in this sample was Claude (40.5%), followed by ChatGPT (29.2%) and Perplexity (26.0%), though this ranking likely reflects sampling characteristics. Despite high adoption, 59.2% typically did not verify AI outputs before use, and 40.2% had never heard that AI can generate fabricated scientific references. In behavioral vignettes, 36.5% assumed convincing AI generated references were authentic, and 54.2% would continue using remaining AI content after discovering one fabricated reference. Formal research training was strongly associated with consistent disclosure (51.7% vs. 17.1%; chi square=48.43, p less than 0.001). Role, daily use frequency, and research training were not significantly associated with verification behavior. Early career medical researchers in Pakistan demonstrate high AI adoption alongside incomplete hallucination awareness and infrequent verification, a pattern that may carry implications for research integrity. Formal training was the only factor significantly associated with consistent disclosure. Integration of AI literacy into medical curricula and institutional governance frameworks merits consideration.

Objective. Biomedical knowledge graphs (KGs) such as PrimeKG, Hetionet, UMLS, and PharmGKB are increasingly used as the substrate for downstream machine-learning, retrieval-augmented generation, drug-repurposing, and electronic health record (EHR) augmentation pipelines. The dominant assumption in published work is that integrating two or more such KGs is a tractable engineering step solved by identifier (ID) matching. This paper interrogates that assumption empirically. We quantify how much concept overlap survives realistic alignment, and we characterize the new failure modes introduced by the methods that practitioners reach for when ID matching is insufficient. Materials and Methods. We compared four widely used biomedical KGs (PrimeKG, Hetionet v1.0, the full UMLS Metathesaurus, and PharmGKB) across eleven node types using a tiered alignment pipeline: (1) direct ID matching for nodes sharing a primary vocabulary; (2) cross-ontology bridging using standard mappings (e.g., MONDO-DOID, HPO-UMLS, HPO-UMLS-MeSH for side effects, NCBI Gene-HGNC-UMLS, UBERON-FMA/SNOMEDCT_US/NCI/MeSH for anatomy); (3) ClinicalBERT cosine-similarity grouping at threshold >= 0.98 for over-segmented disease nodes, with a deterministic suffix-stripping canonicalizer; (4) exact name matching for ontology-poor types (anatomy, REACTOME pathways); and (5) embedding-based fuzzy matching with UMLS lookup (SapBERT and ClinicalBERT) for free-text microbiome concepts. We applied the pipeline to a 698-concept gut-microbiome benchmark spanning taxa, pathways, and disease labels, validated grouping decisions against the curated SSSOM mappings released by the MONDO project, and audited the ClinicalBERT consolidation against five clinical-genetics case studies drawn from the literature. Results. Per-type pairwise coverage was strikingly asymmetric. Genes/proteins and the three Gene Ontology categories aligned cleanly across PrimeKG and Hetionet (mutual coverage 94-99%), but disease overlap was sparse: only 0.7% of PrimeKG individual disease nodes mapped to Hetionet, rising to 2.0% after MONDO grouping (versus 78.7% and 18.4% from the Hetionet side). PrimeKG-to-UMLS coverage spanned 100% (effect/phenotype via HPO) down to 20.8% (REACTOME pathways), with drugs at 73.7% and anatomy at 58.8%. PrimeKG-to-PharmGKB drug coverage required up to two bridging hops (DrugBank -> UMLS -> RxNorm/ATC/MeSH). Bigger was not uniformly more complete: on a 698-concept microbiome drug benchmark, Hetionet missed 0 concepts while PrimeKG missed 16. ClinicalBERT-based grouping consolidated 22,205 raw MONDO disease nodes into 17,080 groups but introduced three reproducible failure modes documented in case studies: (i) peer over-merging: for example, all 22 osteogenesis imperfecta subtypes collapsed into a single node despite distinct severity classes; (ii) parent-child collapse: e.g. acute myeloid leukemia merged with myeloid leukemia, erasing the acute/chronic distinction that drives clinical management; and (iii) lexical false positives: neurofibromatosis and schwannomatosis grouped together despite cellular-pathology differences. Discussion. Identifier matching alone is a weak baseline for biomedical KG integration. Cross-ontology bridges and embedding-based consolidation expand coverage but do so at the cost of clinically meaningful resolution, and the resulting failures are systematic rather than random. Reporting only aggregate coverage statistics obscures these losses, which propagate silently into downstream tasks. Conclusion. We provide reusable per-type coverage tables, a taxonomy of three integration failure modes, and concrete recommendations for downstream studies that depend on a unified biomedical KG. We argue that future KG integration work should report per-type coverage and per-cluster confidence rather than aggregate match rates.

Vocal biomarkers, encompassing voice and speech, have largely been developed for individual conditions in isolation, limiting their generalizability across diseases and recording settings. To address this, we introduce VoiceFM, a contrastive model that learns general-purpose clinical voice representations by aligning audio embeddings with rich clinical metadata. Using the Bridge2AI-Voice dataset (984 primarily English-speaking adult participants, 846 used for training and 138 held out as a temporally separated validation cohort, 40,056 recordings totaling 176 hours across 5 academic medical centers), VoiceFM pairs a fine-tuned Whisper large-v2 encoder with a tabular transformer over 44 clinical features via symmetric InfoNCE loss. Linear probes on frozen VoiceFM embeddings achieve mean AUROC 0.952 +/- 0.005 across five evaluation tasks (control vs disease screening plus four disease categories), significantly outperforming Frozen Whisper (0.926 +/- 0.013, p = 0.013), Frozen HuBERT (0.885 +/- 0.017, p = 0.0009), and the contrastively trained VoiceFM-HuBERT (0.938 +/- 0.006, p = 0.012). On the 138-participant held-out cohort, VoiceFM-Whisper achieves AUROCs of 0.99 for Alzheimer's/dementia/MCI and 0.89 for airway stenosis, demonstrating that the learned representations generalize to participants the model has never seen. VoiceFM representations transfer to three external datasets without retraining and improve few-shot classification. Recording task attribution identifies a small set of speech tasks that match or exceed the full battery's performance, suggesting shorter screening protocols are feasible. Trained predominantly on English audio, VoiceFM transfers without fine-tuning to Spanish-language Parkinson's disease (PD) detection (NeuroVoz, 107 participants, AUROC 0.93 +/- 0.02), with the signal dominated by articulatory rather than phonatory features. A fine-tuned classifier achieves participant-level AUROC 0.87 (sustained 0.85, countdown 0.80) on the mPower smartphone study (585 held-out participants). Together, these results show that contrastive alignment between voice and rich clinical metadata can serve as the basis for a clinical voice foundation model, producing a single set of transferable representations that generalize across diseases, languages, recording conditions, and patients enrolled after model freeze.

Background and Objective: Access to real-world electronic health records (EHRs) remains limited by privacy, governance and annotation constraints, hindering the development of clinical natural language processing models. Realistic synthetic progress notes may provide EHR-like corpora that preserve clinically rigorous information on diagnoses, treatments, symptoms, imaging, laboratory findings and therapeutic trajectories without relying directly on sensitive patient records. This study evaluates whether large language models (LLMs) can generate realistic Spanish prostate cancer progress notes from published case reports, preserving clinical content, temporality and hospital-style conventions.

Amitriptyline is commonly prescribed for chronic pain, yet treatment response and tolerability vary substantially. Genetic variation in CYP2C19 and CYP2D6 influences amitriptyline metabolism, but evidence linking pharmacogene status to clinical outcomes in chronic pain is limited. Amitriptyline is typically prescribed for chronic pain at lower doses than for depression, which may reduce pharmacogenomic effects on clinical outcomes. We analysed 1,146 participants with chronic pain from the Australian Genetics of Depression Study who reported amitriptyline use, treatment outcomes, and genotype data. Metaboliser phenotypes were assigned using PharmCAT. Associations with self-reported effectiveness and discontinuation due to side effects were examined using regression models adjusted for age and sex. Only CYP2C19 intermediate metabolisers showed nominally lower odds of discontinuation and reduced likelihood of reporting moderate effectiveness. Overall, pharmacogenetic phenotypes were not significantly associated with patient-reported amitriptyline outcomes in chronic pain, potentially reflecting the lower doses typically prescribed for pain management.

Although GLP1/GIP receptor agonists demonstrate unprecedented weight loss efficacy, their rapid clinical adoption has revealed significant real-world tolerability challenges. To evaluate their dynamic safety profiles, we developed a macro to micro pharmacovigilance framework by combining global FAERS reports with local UT Physician EHR. Macroscopically, we distilled 17 shared adverse events across the drug class from FAERS with disproportionality analysis. Microscopically, local EHR data (289,655 longitudinal treatment sessions across 71,316 patients) revealed 51.6% of GLP1 sessions terminated within 90 days. Furthermore, temporal stratified logistic regression demonstrated that initial exposure (0 to 30 days) correlated strongly with nausea and vomiting, which attenuated in extended sessions, whereas extended exposure (>2 years) uncovered late onset risks, notably incident hepatic steatosis. Ultimately, this time aware framework reveals that GLP1 safety profiles are profoundly duration dependent, providing critical insights into both acute intolerances and long-term medication safety.

A closed-loop quality system deployed across thirteen US hospital sites resolved physician complaints with zero regressions on 42 tracked cases across 1,089 optimization iterations, while a deterministic assembly-agent replacement cut H+P trace latency from 19.6 s to 10.8 s (-8.8 s, 95% CI [-10.5, -7.1] s; n = 100 pre, n = 100 post). We report four observations and an architectural follow-through. First, the same binary-check instrument produces opposite outcomes depending on the question asked: "maximize this score" produces structurally-correct notes that physicians reject (Spearman rho = -0.077, 95% CI [-0.40, 0.26], n = 36); "did this specific fabrication stop?" produces rater-invariant deployment decisions. Second, in our pipeline, assembly-stage agents did not respond to prompt optimization the way reasoning agents did: four consecutive optimization attempts produced 18-28 point regressions. Third, physician preference is rater-fragile at typical clinical-AI calibration sample sizes (Cohen's kappa = 0.028 between two board-certified physicians, 95% CI [-0.30, 0.36] on n = 35 overlapping pairs). Fourth, the architectural punchline: six weeks after the prediction, the LLM call at the chart-assembly step was replaced with a deterministic renderer (sub-500-character template plus sandboxed scripting), lifting the defect-free rate on a 51-case holdout from 49% to 84%. We introduce a Pareto-with-absolute-floors acceptance rule (multi-axis commit with severity-class categorical vetoes) as a methodological contribution distinct from scalar-reward acceptance in standard prompt-optimization frameworks. Cross-iteration rejection memory prevents the loop from re-proposing edits already rejected three or more times. A reproducibility bundle (anonymized ablation per-case counts, bootstrap-CI data, analysis scripts) is released under CC BY 4.0 at github.com/sayvant/SQS-Auditor-paper-data.

Background: Traditional diagnostic models lack explainability, while multimodal language models prone to hallucination remain unsafe for medical education. An interactive, risk-free artificial intelligence framework is required to serve as a reliable clinical mentor for radiology trainees. Methods: We propose a multi-agent architecture decoupling deterministic image analysis from generative consultation. Specialized computer vision models perform anatomical localization and pathological segmentation. These quantitative outputs are synthesized into a structured payload, which grounds a locally hosted large language model (LLaVA 7B) using strict prompt guardrails and prerequisite protocols. Results: The system effectively eliminates visual hallucinations by intercepting unanchored queries. The artificial intelligence tutor successfully contextualizes spatial anomalies and baseline metrics, generating accurate conversational explanations and formally structured radiology reports while strictly enforcing medical safety disclaimers. Discussion and Conclusion: By anchoring language generation exclusively to verified algorithmic realities, this framework transforms opaque diagnostic models into safe, interactive educational simulators. This establishes a highly reliable paradigm for integrating explainable artificial intelligence into medical training.

The availability of electronic health records has facilitated data-driven approaches to the understanding of multimorbidity, with clustering becoming a common tool for uncovering relevant groups of associated conditions. Previous studies, however, have found challenges in their reproducibility, with wide disparity in the reported clusters. At the core of this issue lays a vagueness of the definition of a cluster, leading to a lack of standards in their methods and evaluation, while implementation details are often not completely reported or explicit in their assumptions. We present a methodological pipeline that can be adapted to different cluster definitions (e.g. multiple cluster membership or clusters where all nodes are mutually associated) and a set of scores that can be composed into an evaluation metric that explicitly incorporates assumptions that align with the research aims. We apply our pipeline to a healthcare dataset of over 7 million patients in England and show how clusters may drastically differ when varying the parameter choices, exposing the risks of reporting a single clustering realisation. Our methodological pipeline, evaluation framework, and tools for analysis and network visualisation serve as a reference to transparently explore and align methodological decisions to the aims of multimorbidity clustering, contributing to overcome the reproducibility challenges of the field.

Blood biomarker models are increasingly used in Alzheimer's disease and related dementia translational research, but predictive performance can be inflated when the same dataset is used for both model development and evaluation. We assess the effect of data double dipping using simulations and NULISA proteomic data from the MYHAT-NI community-based cohort to predict brain amyloid-beta neuroimaging status. In both settings, training AUC increased as more biomarkers were added, while testing AUC peaked earlier and then declined. These findings show that data double dipping can inflate model performance and highlight the need for external validation or internal validation with data partitioning.

Background: Citrin deficiency, caused by biallelic pathogenic variants in SLC25A13, must be identified early to prevent serious complications such as hyperammonemia and liver failure. However, clinical diagnosis is often delayed due to its nonspecific presentation and limited sensitivity of amino acid-based newborn screening methods. Although genome-based evaluations are being investigated to address these issues, concerns about their cost, turnaround time, variant interpretation ability, and data handling highlight the need for a more practical yet reliable alternative. We investigated the feasibility of applying proteomic approach on dried blood spots (DBS), which are routinely used in newborn screening. Methods: We performed untargeted liquid chromatography-tandem mass spectrometry to analyze the proteome of DBS using a previously developed "non-targeted analysis of non-specifically DBS-absorbed proteins" (NANDA) workflow. SLC25A13 protein abundance was quantified in individuals with biallelic loss-of-function mutations, compound loss-of-function/missense mutations, and heterozygous carriers; this was also evaluated in healthy and diseased controls representing relevant differential diagnoses. To leverage proteomic information, we derived a multivariate proteomic signature using feature selection and evaluated its performance with leave-one-out cross-validation. Biological relevance was assessed by enrichment analysis, and complementary transcriptomics was performed using RNA sequencing. Results: A total of 7,474 proteins, including SLC25A13, were consistently detected in DBS. SLC25A13 was undetectable in individuals with biallelic loss-of-function mutations. However, individuals with compound loss-of-function/missense genotypes showed reduced but measurable SLC25A13 levels, comparable to those observed in heterozygous carriers. In contrast, a compact 15-protein signature accurately identified individuals with compound loss-of-function/missense genotypes (AUC, 0.99; sensitivity, 1.00; specificity, 0.95). The signature was enriched for Ca2+-response, and transcriptomics showed downregulation of genes related to multimodal ion channels in affected individuals compared to controls. Conclusions: DBS-based proteomic profiling may assist in the diagnosis of citrin deficiency through SLC25A13-quantification and a biologically plausible multivariate signature. More broadly, this strategy offers a promising new diagnostic layer for protein disorders, providing a proteomic readout in a clinically practical DBS format with potential utility for future diagnostic and screening applications.

Background: The All of Us Research Program represents a rich resource for cancer epidemiology research, with over 400,000 participants with whole genome sequences linked to electronic health records (EHR). Large cancer datasets often focus exclusively on cases without controls and neglect pre-diagnosis healthcare occurrences. Here, we perform a phenome-wide association study (PheWAS) of EHR data at least 1 year pre-diagnosis between cancer cases and matched controls, revealing co-occurring and mutually exclusive phenotypes. Methods: We identified 55,000+ cancer cases across 21 cancer types in All of Us version 8. To eliminate age-related confounding, we implemented a two-stage matching and censoring strategy: loose matching on demographics to establish index dates and cohort comparability, followed by right-censoring of EHR data (excluding 1 year pre-diagnosis/index), then 1:2 matching to address residual demographic imbalance. We tested associations between 23,193 cancer cases, 46,386 matched controls and approximately 1,600 clinical phenotypes using logistic regression adjusted for sex at birth, self-reported race, age at diagnosis/index date, and two censored EHR metrics: observation window and unique condition count, with Bonferroni correction for multiple testing. Results: Our analysis identified 232 significantly associated phenotypes, confirming established cancer risk factors including elevated prostate specific antigen (OR = 2.92, 95% CI: 2.65-3.23; p-value=1.8x10-101) and multinodular goiter (OR = 1.73, 95% CI: 1.56-1.91; p-value=6.7x10-27). Further investigation into the relationship between several phenotypes with seeming inverse effects is warranted. Conclusions: This PheWAS of EHR data at least 1 year pre-diagnosis leveraged the diversity of All of Us to examine how clinical phenotypes prior to cancer diagnosis vary across cancer types and racial groups. Our findings validate All of Us as a robust platform for cancer epidemiology research, confirming established risk factors at scale across diverse populations. This work provides methodological insights for EHR-based susceptibility analyses and demonstrates the value of agnostic phenome-wide approaches for generating hypotheses in precision medicine.

Spousal caregivers of individuals with Alzheimers disease and related dementias frequently experience elevated perceived stress, caregiver burden, and loneliness, which are associated with adverse health outcomes. Early identification is therefore critical for timely intervention. Existing approaches commonly rely on wearable sensor data and standardized psychological questionnaires, while recent multimodal methods aim to improve prediction by integrating behavioral and linguistic information. In this study, we explored three modality configurations, wearable-derived features, interview-based text, and their combination, to classify caregiver psychological risk using the Perceived Stress Scale (PSS), Zarit Burden Interview, and UCLA Loneliness Scale. We compared traditional machine learning models and large language models (LLMs) (Gemini 2.0, Llama 4, and GPT-4o) under psychometrician-centered and caregiver-centered prompting strategies. Traditional machine learning models performed better under multimodal settings, while LLMs achieved stronger performance with Interview-Only input. We further demonstrate that PSS was the most predictable construct and prompting strategies substantially influenced LLM performance.

Pharmacogenomics (PGx) offers a pathway towards personalised medicine, which relies on health consumer involvement in making informed decisions. As consumers increasingly seek health information online, high-quality digital resources are essential to support informed consent and shared decision making. The complexity of PGx and widespread limitations in health literacy raise concerns about whether existing consumer-facing online PGx resources are understandable and sufficiently comprehensive. This study evaluates the readability, visual design, and informational quality of publicly available online written PGx health information. Twenty-three webpages met inclusion criteria. The mean readability corresponded to approximately 15 years of formal education (university level), substantially exceeding the Australian Government's recommended Year 7 reading level for public health materials. Informational quality was generally low, with most webpages being rated as poor or very poor. In contrast, visual design quality was relatively strong, with webpages achieving on average around three-quarters of the criteria. Although the visual presentation of PGx webpages is generally professional, their high reading difficulty and limited discussion of treatment choices and uncertainties reduce their usefulness for health consumer education. Improving readability, clearly communicating risks and limitations, and incorporating decision-support features may enhance the ability of online resources to support informed consent and shared decision making.

Longitudinal evaluations of national electronic health record repositories often track document counts alone, obscuring changes in content size, structure and standards implementation. We decomposed growth in the Estonian Health Information System across document counts, per-document size, section-level structure and version uptake in a 10% random population sample of 4.97 million HL7 Clinical Document Architecture Release 2 documents from 147,819 patients, spanning 2012--2019 and four prespecified document types. Growth patterns differed by document type. Inpatient summaries increased 48.5% in total content volume despite a 2.4% decline in document counts. Section presence and within-section content were highly skewed; 44.6% of 892 data locations carried one fixed value. Code-system diversity increased from 45 to 79, and version uptake took years: inpatient summaries reached 80% organisational uptake after a median 44 months (95% CI 11--78). This decomposition can guide extraction pipelines, secondary use and standards governance in CDA- and FHIR-based repositories.